{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T20:31:40Z","timestamp":1781123500218,"version":"3.54.1"},"reference-count":22,"publisher":"SAGE Publications","issue":"8","license":[{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T00:00:00Z","timestamp":1748822400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"name":"Otsuka Pharmaceutical Development & Commercialization, Inc","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Can J Psychiatry"],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>\n                      To compare the short-term safety and efficacy of centanafadine, an investigational treatment, versus long-acting controlled-release methylphenidate hydrochloride (methylphenidate, Foquest\n                      <jats:sup>\u00ae<\/jats:sup>\n                      ) among adult patients with attention-deficit\/hyperactivity disorder (ADHD), using matching-adjusted indirect comparison (MAIC).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This anchored MAIC used pooled individual patient data (IPD) from two centanafadine trials (NCT03605680, NCT03605836) and published aggregate data from one methylphenidate trial (NCT02139124). Using propensity scores, IPD from the centanafadine trials were reweighted to match the aggregate baseline characteristics of the methylphenidate trial. Safety and efficacy outcomes were compared at Week 4. Safety outcomes were the rates of adverse events reported by \u22655% of patients in any treatment group in either trial with an incidence twice that of the placebo. The efficacy outcome was the mean change from baseline in Adult ADHD Investigator Symptom Rating Scale (AISRS)\/ADHD Rating Scale\u20135 (ADHD-RS-5) score at Week 4.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>After matching, no significant differences in baseline characteristics were observed across trials. Relative to methylphenidate, centanafadine exhibited a better safety profile, with a significantly lower risk of insomnia (risk difference in percentage points: \u22129.46 points) and initial insomnia (\u22124.68 points). There was no significant difference in efficacy across treatments as measured by the mean change from baseline in AISRS\/ADHD-RS-5 score.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>In this MAIC, centanafadine was associated with a lower risk of insomnia and comparable (i.e., nondifferent) efficacy compared to methylphenidate at Week 4. Information on the comparative safety and efficacy of ADHD treatments in the adult population will help inform personalized treatment decisions given the range of treatment options with varying attributes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/07067437251342279","type":"journal-article","created":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T03:23:43Z","timestamp":1748834623000},"page":"629-638","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":2,"title":["A Matching-Adjusted Indirect Comparison (MAIC) of Centanafadine versus Methylphenidate Hydrochloride in Adults with Attention-Deficit\/Hyperactivity Disorder (ADHD): Short-Term Safety and Efficacy Outcomes: Comparaison indirecte ajust\u00e9e par appariement (MAIC) entre centanafadine et le chlorhydrate de m\u00e9thylph\u00e9nidate chez les adultes atteints d\u2019un trouble d\u00e9ficitaire de l'attention avec ou sans hyperactivit\u00e9 (TDAH) : R\u00e9sultats en mati\u00e8re d\u2019innocuit\u00e9 et d\u2019efficacit\u00e9 \u00e0 court terme"],"prefix":"10.1177","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-7892-5005","authenticated-orcid":false,"given":"Jeff","family":"Schein","sequence":"first","affiliation":[{"name":"Global Value & Real World Evidence, Otsuka Pharmaceutical Development & Commercialization, Inc."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1360-8133","authenticated-orcid":false,"given":"Maryaline","family":"Catillon","sequence":"additional","affiliation":[{"name":"HEOR, Analysis Group, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chunyi","family":"Xu","sequence":"additional","affiliation":[{"name":"HEOR, Analysis Group, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alice","family":"Qu","sequence":"additional","affiliation":[{"name":"HEOR, Analysis Group, Inc., New York, NY, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana\u00efs","family":"Lemyre","sequence":"additional","affiliation":[{"name":"HEOR, Analysis Group, Inc., Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marjolaine","family":"Gauthier-Loiselle","sequence":"additional","affiliation":[{"name":"HEOR, Analysis Group, Inc., Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Cloutier","sequence":"additional","affiliation":[{"name":"HEOR, Analysis Group, Inc., Montr\u00e9al, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ann","family":"Childress","sequence":"additional","affiliation":[{"name":"Psychiatry, Center for Psychiatry and Behavioral Medicine, Las Vegas, NV, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2025,6,2]]},"reference":[{"key":"e_1_3_3_2_2","first-page":"1377","volume-title":"American Psychiatric association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision","author":"American Psychiatric Association","year":"2022","unstructured":"American Psychiatric Association. American Psychiatric association. Diagnostic and statistical manual of mental disorders, fifth edition, text revision. Washington, DC: American Psychiatric Association; 2022:1377."},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/s11920-008-0065-7"},{"key":"e_1_3_3_4_2","unstructured":"Canadian ADHD Resource Alliance (CADDRA). Canadian ADHD Practice Guidelines. January 2021;2021:112. https:\/\/adhdlearn.caddra.ca\/wp-content\/uploads\/2022\/08\/Canadian-ADHD-Practice-Guidelines-4.1-January-6-2021.pdf"},{"key":"e_1_3_3_5_2","doi-asserted-by":"publisher","DOI":"10.1080\/23279095.2018.1532429"},{"key":"e_1_3_3_6_2","doi-asserted-by":"publisher","DOI":"10.1177\/1087054718799367"},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2023.115449"},{"key":"e_1_3_3_8_2","doi-asserted-by":"publisher","DOI":"10.3390\/brainsci12081051"},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1177\/1087054717720719"},{"issue":"1","key":"e_1_3_3_10_2","first-page":"107","article-title":"Treatment of adults with attention-deficit\/hyperactivity disorder","volume":"4","author":"Kolar D","year":"2008","unstructured":"Kolar D, Keller A, Golfinopoulos M, Cumyn L, Syer C, Hechtman L. Treatment of adults with attention-deficit\/hyperactivity disorder. Neuropsychiatr Dis Treat. 2008;4(1):107-121. doi:https:\/\/doi.org\/10.2147\/ndt.s1747","journal-title":"Neuropsychiatr Dis Treat"},{"key":"e_1_3_3_11_2","unstructured":"Elvium Life Sciences. FOQUEST\u00ae (methylphenidate hydrochloride) Product Monograph. Accessed April 10 2024. https:\/\/pdf.hres.ca\/dpd_pm\/00068572.PDF"},{"key":"e_1_3_3_12_2","unstructured":"Health Canada. Regulatory Decision Summary \u2013 Foquest. Accessed April 10 2024. https:\/\/hpr-rps.hres.ca\/reg-content\/regulatory-decision-summary-detail.php?linkID=RDS00376"},{"key":"e_1_3_3_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/JCP.0000000000001575"},{"key":"e_1_3_3_14_2","unstructured":"A Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-release Tablets in Adults With Attention-Deficit\/Hyperactivity Disorder. https:\/\/clinicaltrials.gov\/study\/NCT03605849?intr=centanafadine&aggFilters=phase:3&rank=4"},{"key":"e_1_3_3_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2012.05.004"},{"issue":"3","key":"e_1_3_3_16_2","first-page":"1","article-title":"Assessment of centanafadine in adults with attention-deficit\/hyperactivity disorder: a matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release","volume":"30","author":"Schein J","year":"2024","unstructured":"Schein J, Cloutier M, Gauthier-Loiselle M, et al. Assessment of centanafadine in adults with attention-deficit\/hyperactivity disorder: a matching-adjusted indirect comparison vs lisdexamfetamine dimesylate, atomoxetine hydrochloride, and viloxazine extended-release. J Manag Care Spec Pharm. 2024;30(3):1-13.","journal-title":"J Manag Care Spec Pharm"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","unstructured":"Schein J Cloutier M Gauthier-Loiselle M et al. Assessment of centanafadine in adults with ADHD: a matching adjusted indirect comparison versus methylphenidate hydrochloride extended release (Concerta). 2024.","DOI":"10.1080\/03007995.2024.2373883"},{"key":"e_1_3_3_18_2","unstructured":"Clinicaltrials.gov. The Efficacy and Safety of PRC-063 in Adult ADHD Patients. Updated 05\/07\/2019. [accessed 16 April 2024]. https:\/\/clinicaltrials.gov\/study\/NCT02139124"},{"issue":"10","key":"e_1_3_3_19_2","first-page":"13","article-title":"Quality of life in patients suffering from insomnia","volume":"9","author":"Ishak WW","year":"2012","unstructured":"Ishak WW, Bagot K, Thomas S, et al. Quality of life in patients suffering from insomnia. Innov Clin Neurosci. 2012;9(10):13.","journal-title":"Innov Clin Neurosci."},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2022.2122228"},{"key":"e_1_3_3_21_2","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S467724"},{"key":"e_1_3_3_22_2","doi-asserted-by":"publisher","unstructured":"Schein J Cloutier M Gauthier-Loiselle M et al. Treatment preferences of physicians treating adult patients with attention-deficit\/hyperactivity disorder in the United States and Canada: A discrete choice experiment. Neurol Ther. 2024;14(1):193-210. doi: 10.1007\/s40120-024-00681-y","DOI":"10.1007\/s40120-024-00681-y"},{"key":"e_1_3_3_23_2","first-page":"1543","article-title":"Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder\u2013a systematic literature review","author":"Gajria K","year":"2014","unstructured":"Gajria K, Lu M, Sikirica V, et al. Adherence, persistence, and medication discontinuation in patients with attention-deficit\/hyperactivity disorder\u2013a systematic literature review. Neuropsychiatr Dis Treat. 2014;10:1543-1569.","journal-title":"Neuropsychiatr Dis Treat."}],"container-title":["The Canadian Journal of Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/07067437251342279","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/07067437251342279","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/07067437251342279","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T16:15:58Z","timestamp":1777392958000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/07067437251342279"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,2]]},"references-count":22,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["10.1177\/07067437251342279"],"URL":"https:\/\/doi.org\/10.1177\/07067437251342279","relation":{},"ISSN":["0706-7437","1497-0015"],"issn-type":[{"value":"0706-7437","type":"print"},{"value":"1497-0015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,2]]}}}